Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Secukinumab did not show clinical efficacy versus placebo when treating patients with active, moderate-to-severe GO.
Authors
- Christian Vorländer
- Jan Wolf
- Andreas Clemens (ORCID: https://orcid.org/0000-0001-6192-1557)
- Harald Lahner (ORCID: https://orcid.org/0009-0008-0843-1565)
- Anja Eckstein (ORCID: https://orcid.org/0000-0002-8971-1444)
- Steven Draikiwicz
- Katrin Lorenz (ORCID: https://orcid.org/0000-0002-1755-7396)
- Anna Beck (ORCID: https://orcid.org/0000-0003-0365-3819)
- Heike M. Elflein (ORCID: https://orcid.org/0000-0003-4630-6438)
- Lea D. Grauhan (ORCID: https://orcid.org/0000-0003-1772-2002)
- Wolf A. Lagrèze (ORCID: https://orcid.org/0000-0002-3558-5905)
- George J. Kahaly (ORCID: https://orcid.org/0000-0003-0441-430X)
- Christelle C Pieterse
- Maximilian Luffy
- Michael P. Schittkowski
- H Michel
- Brian Porter
- Maximilian Reinhardt
- Maren Horn (ORCID: https://orcid.org/0009-0009-1990-9218)
- Susanne Pitz
- Ahmed E Othman
- Tim Bleul
Institutions
- Novartis (Switzerland) (CH)
- Johannes Gutenberg University Mainz (DE)
- University Medical Center Freiburg (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Bürgerhospital Frankfurt am Main (DE)
- Universitätsmedizin Göttingen (DE)
- Novartis (United States) (US)
- Essen University Hospital (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1210/clinem/dgaf655
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Argenx
- Novartis Pharma